Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.41 |
| ▸ | CTSS | P25774 | 6/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30422267 | 0.88 | CA1 (0.42) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL29265449 | 0.88 | CA1 (0.42) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL19412369 | 0.87 | CA1 (0.38) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL19412367 | 0.87 | CA1 (0.38) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL28648145 | 0.85 | CYP2D6 (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL28648146 | 0.85 | CYP2D6 (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL19412345 | 0.85 | CA1 (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL19412348 | 0.85 | CA1 (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL4936593 | 0.84 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1853923 | 0.84 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | CTSK 3724/4885CTSS 3902/4885CA1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.